The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience

Gülsüm Akgün Çağlıyan; Oktay Bilgir

Kronik myeloproliferatif neoplazili hastalarda JAK2V617F mutasyon ve tromboemboli durumlarının değerlendirilmesi;tek merkez deneyimi

Year 2014, Issue: 3, 196 - 200, 01.10.2014

Abstract

AMAÇ: Kronik Miyeloproliferatif neoplazm (KMPN), hemostaz ve tromboz anomalileri ve akut lösemiye ilerleyebilen klonal bir hastalıktır. PV(polisitemi vera), ET (esansiyel trombositoz) ve IMF (ıdıoyapatik myelofibrozis) bcr- abl negatif KMPN’lerdir.YÖNTEMLER: Bu çalışmada 2008-2013 yılları arasında İzmir Bozyaka Eğitim Araştırma Hastanesi hematoloji kliniğinde takip edilen ve bcr-abl negatif kronik myeloproliferatif neoplazi (KMPN) tanısı alan 128 olgu değerlendirildi. Hastaların demografik özellikleri, laboratuar sonuçları, JAK2V617F mutasyon durumları ve kullandığı tedaviler hasta dosyalarından geriye dönük olarak kaydedildiBULGULAR: Hastaların 63‘ü kadın (%49.2), 65‘i erkek (%50.8) idi. Yaşları 23–87 yaş aralığında ve ortanca yaş 65 idi. 87 hastanın (%68) JAK2V617F mutasyonu pozitif, 41 hastanın (%32) ise JAK2V617F mutasyonu negatif bulundu. JAK2V617F mutasyonu pozitif olan hastaların %42.5’inde (37/87), JAK2V617F mutasyonu negatif olan hastaların ise %14.9’unda (13/87) trombotik olay saptandı. JAK2 mutasyonu pozitif olan hastalarda trombotik olayların daha sık olması istatiksel olarak anlamlı bulundu (p=0.003). En çok görülen trombotik olayın koroner arter hastalığı olduğu görüldü (20/50).SONUÇ: Sonuç olarak, KMPN’li hastalarda JAK2V617F gen mutasyonu tanı ve komplikasyonlar için önemli bir bulgudur.

Keywords

Myeloproliferatif Neoplazi, JAK2 mutasyonu, Tromboemboli

The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience

Year 2014, Issue: 3, 196 - 200, 01.10.2014

Gülsüm Akgün Çağlıyan Oktay Bilgir

Abstract

OBJECTIVE: Myeloproliferative neoplasms are clonal diseases that associated with hemostasis and thrombosis anomalies as well as progression to acute leukemia. PV, ET and IMF are bcr- abl negative myeloproliferative neoplasmsMETHODS: In this study, we evaluated 128 bcr-abl negative CMPN patients, was followed in Izmir Bozyaka Traning and Research Hospital, Department of Hematology, in between 2008 and 2013. We investigated; demographic and laboratory information, the state of JAK2V617F mutation and therapies, by retrospectively. RESULTS: Of the total of 128 patients, 63 patients were female and 65 were male. All of patients’s ages were between 23-87 years old. Median age was 65 years old. 87 of patients had JAK2V617F positive. 41 patients had JAK2V617F negative. JAK2V617F positive (37/87) patients and JAK2V617F negative patients (13/87) had thrombotic events. It was significant clinically and statistically in JAK2V617F mutation positive patients who had more thrombotic events (p=0.003). The most of thrombotic events was coroner arter diseases (20/50).CONCLUSION: In conclusion, JAK2V617F gene mutation is an important finding for diagnosis and complication in CMPN patients.

Keywords

Myeloproliferative Neoplasm, JAK2 mutation, Thromboembolism

There are 0 citations in total.

Details

Other ID	JA87JT59JZ
Journal Section	Research Article
Authors	Gülsüm Akgün Çağlıyan Oktay Bilgir This is me
Publication Date	October 1, 2014
Submission Date	October 1, 2014
Published in Issue	Year 2014 Issue: 3

Cite

APA	Çağlıyan, G. A., & Bilgir, O. (2014). The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience. Pamukkale Medical Journal(3), 196-200.
AMA	Çağlıyan GA, Bilgir O. The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience. Pam Med J. October 2014;(3):196-200.
Chicago	Çağlıyan, Gülsüm Akgün, and Oktay Bilgir. “The Evaluation of JAK2V617F Mutation and Thromboembolism in Chronic Myeloproliferative Neoplasia Patients; A Single Center Experience”. Pamukkale Medical Journal, no. 3 (October 2014): 196-200.
EndNote	Çağlıyan GA, Bilgir O (October 1, 2014) The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience. Pamukkale Medical Journal 3 196–200.
IEEE	G. A. Çağlıyan and O. Bilgir, “The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience”, Pam Med J, no. 3, pp. 196–200, October 2014.
ISNAD	Çağlıyan, Gülsüm Akgün - Bilgir, Oktay. “The Evaluation of JAK2V617F Mutation and Thromboembolism in Chronic Myeloproliferative Neoplasia Patients; A Single Center Experience”. Pamukkale Medical Journal 3 (October 2014), 196-200.
JAMA	Çağlıyan GA, Bilgir O. The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience. Pam Med J. 2014;:196–200.
MLA	Çağlıyan, Gülsüm Akgün and Oktay Bilgir. “The Evaluation of JAK2V617F Mutation and Thromboembolism in Chronic Myeloproliferative Neoplasia Patients; A Single Center Experience”. Pamukkale Medical Journal, no. 3, 2014, pp. 196-00.
Vancouver	Çağlıyan GA, Bilgir O. The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience. Pam Med J. 2014(3):196-200.